Amgen (AMGN) Highlights Cost-Effectiveness of Repatha in New Car
Amgen (AMGN) Highlights Cost-Effectiveness of Repatha in New Car GuruFocus
Covered in this story
Analyst targets on Amgen
- Freedom Broker: $460 → $470 by Nov 2027 · Hold via Investing.com
- Oppenheimer: $439 → $480 by Oct 2027 · Outperform via Investing.com India
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 30 Mar 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.